The mammalian nuclear poly(A) binding protein, PABPN1, carries thirteen asymmetrically dimethylated arginine residues in its C-terminal domain. By fractionation of cell extracts, we found that protein arginine methyltransferases (PRMTs) 1, -3 and -6 are responsible for the modification of PABPN1. Recombinant PRMTs 1, -3 and -6 also methylated PABPN1. Our data suggest that these enzymes act on their own and additional polypeptides are not involved in recognizing PABPN1 as a substrate. PRMT1 is the predominant methyltransferase acting on PABPN1. Nevertheless, PABPN1 was almost fully methylated in PRMT1-/- cells; thus, PRMT3 and -6 suffice for methylation. In contrast to PABPN1, the protein hnRNP K is selectively methylated only by PRMT1. Efficient methylation of synthetic peptides derived from PABPN1 or hnRNP K suggested that PRMT1, -3 and -6 recognize their substrates by interacting with local amino acid sequences and not with additional domains of the substrates. However, the use of fusion proteins suggested that the inability of PRMT3 and -6 to modify hnRNP K is due to structural masking of the methyl-accepting amino acid sequences by neighboring domains. Mutations leading to intracellular aggregation of PABPN1 cause the disease oculopharyngeal muscular dystrophy. The C-terminal domain containing the methylated arginine residues is known to promote PAPBN1 self-assocation, and arginine methylation has been reported to inhibit self-association of an orthologous protein. Thus, arginine methylation might be relevant for OPMD. However, in two different types of assays we have been unable to detect any effect of arginine methylation on the aggregation of bovine PABPN1.